Market Overview - The market experienced fluctuations with the ChiNext Index dropping over 1% and a total transaction volume of 1.68 trillion [1] - The superhard materials sector showed resilience, with Huanghe Xuanfeng hitting the daily limit and Sifangda rising over 10% [1] - The coal sector saw collective gains, with companies like Dayou Energy and Antai Group reaching the daily limit [1] - The flu prevention concept was active, with Yisheng Pharmaceutical hitting the daily limit and Yue Wannianqing rising over 10% [1] - Overall, more stocks declined than rose, with over 3,800 stocks in the Shanghai, Shenzhen, and Beijing markets in the red [1] Hot Topics Cultivated Diamonds - The cultivated diamond sector surged, with Huanghe Xuanfeng and Guoji Heavy Industry hitting the daily limit, and Sifangda increasing by 15% [4] - The demand for diamond as a heat dissipation material is expected to grow significantly due to advancements in semiconductor technology [5] - The diamond heat dissipation market is projected to expand from $0.37 million in 2025 to $15.2 billion by 2030, indicating explosive growth [6] Coal Sector - The coal sector performed well, with Antai Group achieving two consecutive daily limits and companies like Huitian Thermal Power and New Dazhou A also hitting the daily limit [7] - A cold wave affecting central and eastern China has led to significant temperature drops, boosting energy procurement demand [7] - Analysts expect coal prices to maintain upward momentum due to stricter safety regulations and increased demand during the winter heating season [8] Pharmaceutical Sector - The pharmaceutical sector was active again, with Haiwang Biological achieving six consecutive daily limits and companies like Ruikang Pharmaceutical and Yisheng Pharmaceutical hitting the daily limit [9] - The high transmissibility of the flu virus has created a surge in demand for antiviral medications and related products [10] - Retail pharmacies are expected to benefit from increased demand for protective products such as masks and disinfectants [10]

Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

Group 1 - The flu-related concept stocks experienced significant fluctuations, with Yingke Group hitting the daily limit up [1] - Haiwang Bio and Yisheng Pharmaceutical also reached the daily limit up, indicating strong market interest [1] - Yue Wannianqing saw an increase of over 10%, while companies like Guangji Pharmaceutical, Panlong Pharmaceutical, and Jindike also experienced gains [1]

数据显示，诺安基金旗下1只基金位居益盛药业十大流通股东。诺安多策略混合A（320016）三季度新 进十大流通股东，持有股数198.63万股，占流通股的比例为0.86%。根据测算，今日浮亏损失约83.42万 元。连续4天下跌期间浮亏损失85.41万元。 11月21日，益盛药业跌5.12%，截至发稿，报7.79元/股，成交5162.70万元，换手率2.79%，总市值25.78 亿元。益盛药业股价已经连续4天下跌，区间累计跌幅4.98%。 资料显示，吉林省集安益盛药业股份有限公司位于吉林省集安市文化东路17-20号，成立日期1997年6月 11日，上市日期2011年3月18日，公司主营业务涉及中成药研发、生产、销售。主营业务收入构成为： 胶囊类产品47.89%，针剂类产品30.94%，化妆品7.39%，人参类产品6.89%，其他产品6.59%，蜂制品 0.31%。 从益盛药业十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 诺安多策略混合A（ ...

Core Viewpoint - Yisheng Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.66% but a recent decline of 2.12% over the past five trading days [1][2]. Financial Performance - For the period from January to September 2025, Yisheng Pharmaceutical reported a revenue of 476 million yuan, representing a year-on-year decrease of 5.81%. The net profit attributable to shareholders was 24.13 million yuan, down 32.72% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 213 million yuan, with 99.29 million yuan distributed over the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Yisheng Pharmaceutical was 19,700, a decrease of 1.92% from the previous period. The average number of circulating shares per person increased by 1.96% to 11,740 shares [2]. - Notably, as of September 30, 2025, the eighth largest circulating shareholder is the Nuoan Multi-Strategy Mixed A fund, which holds 1.9863 million shares as a new shareholder [3]. Stock Performance - As of November 19, Yisheng Pharmaceutical's stock price was 8.31 yuan per share, with a market capitalization of 2.75 billion yuan. The stock saw a trading volume of 12.1 million yuan and a turnover rate of 0.62% [1].

Meeting Overview - The first temporary shareholders' meeting of Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. was held on November 12, 2025, at 14:30 [4][5] - The meeting was conducted through a combination of on-site voting and online voting [3][6] Attendance - A total of 72 shareholders attended the meeting, representing 135,423,848 shares, which is 40.9195% of the total shares [9] - Among them, 67 shareholders participated via online voting, representing 2,682,500 shares, or 0.8105% of the total shares [9] Resolutions Passed - The meeting approved several key resolutions, including: 1. **Application for Working Capital Loan**: Approved with 98.2932% in favor [11] 2. **Cancellation of Supervisory Board and Amendment of Articles of Association**: Approved with 98.2932% in favor [12] 3. **Amendments to Governance Systems**: Multiple amendments were approved, including: - **Amendment of Shareholders' Meeting Rules**: Approved with 98.3014% in favor [15] - **Amendment of Board Meeting Rules**: Approved with 98.3014% in favor [17] - **Amendment of Independent Director Work System**: Approved with 98.3014% in favor [19] - **Amendment of External Investment Management System**: Approved with 98.3014% in favor [20] - **Amendment of Related Party Transaction Management Measures**: Approved with 98.2977% in favor [21] - **Amendment of Fundraising Management Measures**: Approved with 98.2944% in favor [22] - **Amendment of Financing and External Guarantee Management Measures**: Approved with 98.2944% in favor [23] - **Establishment of Director and Senior Management Compensation Management System**: Approved with 98.2828% in favor [24] - **Amendment of Cumulative Voting Implementation Rules**: Approved with 98.2965% in favor [25] Legal Opinion - The meeting was witnessed by lawyers from Beijing Zhide Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [26] Documents for Reference - The resolutions from the first temporary shareholders' meeting and the legal opinion from Beijing Zhide Law Firm are available for review [27]

Core Points - Yisheng Pharmaceutical announced the election of Tong Xiaole as the employee representative director of the ninth board of directors during the second employee representative conference held on November 12, 2025 [1] Group 1 - The company held its second employee representative conference on November 12, 2025 [1] - The proposal to elect the employee representative director was reviewed and approved by the attending employee representatives [1] - Tong Xiaole was elected to serve as the employee representative director on the ninth board of directors [1]

证券代码：002566 证券简称：益盛药业 公告编号：2025-050 吉林省集安益盛药业股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议的情形。 3、本次股东会采用现场表决、网络投票相结合的方式。 一、会议召开情况 1、召开时间： 现场会议时间：2025年11月12日（星期三）下午14:30。 网络投票时间为：2025年11月12日，其中：通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年11月15日上午9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票的具体时间为2025年11月12日 9:15-15:00期间的任意时间。 2、召开地点：吉林省集安市文化东路17－20号公司四楼会议室。 3、召开方式：本次股东会采用现场表决、网络投票相结合的方式。 4、召集人：吉林省集安益盛药业股份有限公司董事会。 5、主持人：董事长张益胜先生。 6、本次股东会议的召开符 ...

公司第九届董事会第四次会议决议。 特此公告。 吉林省集安益盛药业股份有限公司董事会 吉林省集安益盛药业股份有限公司（以下称"公司"）第九届董事会第四次 会议通知以当面送达、电话、邮件的方式于2025年11月5日向各董事发出，会议 于2025年11月12日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 一、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于补 选董事会提名委员会委员的议案》。 《关于非独立董事辞职暨选举职工代表董事及补选董事会提名委员会委员 的公告》详见巨潮资讯网（www.cninfo.com.cn）及《中国证券报》、《上海证 券报》、《证券时报》。 二、备查文件 证券代码：002566 证券简称：益盛药业 公告编号：2025-052 吉林省集安益盛药业股份有限公司 第九届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 二〇二五年十一月十二日 1 ...

Core Viewpoint - Yisheng Pharmaceutical (SZ 002566) announced the convening of its ninth board meeting on November 12, 2025, to discuss the proposal for the re-election of members of the board's nomination committee [1] Company Summary - For the first half of 2025, Yisheng Pharmaceutical's revenue composition is as follows: 81.06% from the pharmaceutical industry, 10.27% from health products and others, 7.39% from cosmetics, and 1.28% from other sources [1] - As of the report date, Yisheng Pharmaceutical has a market capitalization of 2.8 billion yuan [1]